MICIN

About MICIN

MICIN, Inc. is a Japanese healthtech company founded in 2015 by Seigo Hara. Hara, who holds an MD from the University of Tokyo and an MBA from Stanford University, has a background that includes work at the International Medical Center of Japan, the Health and Global Policy Institute, and McKinsey, reflecting a career dedicated to improving healthcare systems.

The company operates an AI-driven healthtech platform aimed at bridging the gap between daily life and illness by connecting patients with medical professionals online. MICIN's business is structured around four main pillars: a medical experience business, a clinical development digital solutions business, a digital therapeutics business, and an insurance business.

Key products and services include: * **curon Telemedicine Service:** Launched in April 2016, this service allows patients to handle everything from appointments and consultations to payments and prescription delivery online. * **curon Medication Support:** An online service for pharmacies that enables pharmacists to provide medication guidance to patients at home via phone or video call. * **curon Smartpass:** A cashless payment service designed to streamline the in-clinic experience for patients. * **MiROHA:** A platform offering digital solutions for clinical development, designed to support the evolving landscape of pharmaceutical research and development. * **Digital Therapeutics (DTx):** MICIN is developing software-based interventions for disease management, prevention, and treatment. This includes the "MedBridge" application for perioperative care and research into apps for conditions like irritable bowel syndrome. * **MICIN Insurance Inc.:** A subsidiary that offers insurance products, aiming to provide coverage that aligns with modern healthcare advancements and allows individuals to make personalized choices about their medical care.

The company's business model focuses on creating a comprehensive healthcare ecosystem. It caters to patients, doctors, pharmacists, and pharmaceutical companies. By leveraging data and technology, MICIN aims to make healthcare more accessible and personalized, improve the quality of clinical trials, and offer new therapeutic options. As of October 2023, MICIN had raised a total of over 10 billion yen (approximately $99 million) through multiple funding rounds, including a Series C round, to fuel the growth of its various business lines.